Study of CML patients in Kuwait: traits and treatments
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at the health characteristics, other illnesses, and treatment patterns of people with chronic myeloid leukemia (CML) in Kuwait. It aims to help doctors better understand how CML is managed and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
- You must have received at least one type of tyrosine kinase inhibitor (TKI) treatment.
- You must have medical records from the 6 months before your diagnosis date, or from the time you were diagnosed if you were diagnosed recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
This study looks at how chronic myeloid leukemia (CML) affects your daily life and how care is organized in Lombardy hospitals. Researchers want to learn from your experiences to improve care for everyone with CML.
This study looks at how well the 2022 European LeukemiaNet (ELN) guidelines work for adults of Middle Eastern or North African descent who are newly diagnosed with AML. It aims to improve treatment decisions based on your genetic profile and ancestry.
This study is watching how well asciminib (Scemblix) works in real life for people with chronic-phase CML in Saudi Arabia. If you've already tried two or more targeted therapies (TKIs) and recently started asciminib, this study may help doctors understand more about its effectiveness and side effects.
This research study examines blood cells from patients with chronic myelomonocytic leukemia (CMML), a rare blood cancer, to better understand how the disease develops and progresses. By studying your blood cells, researchers hope to learn more about what causes CMML and how to treat it better.
Hear when a new Leukemia, Myeloid, Chronic-Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.